Blood immune cell biomarkers in lung cancer

Riemann, Dagmar; Cwikowski, M; Turzer, Steffi; Giese, Thomas; Grallert, M.; Schütte, Wolfgang; Seliger, Barbara

doi:10.1111/cei.13219

Cited by 54 publications

(53 citation statements)

References 50 publications

(56 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More recent studies have shown that an early decrease in NLR during treatment with PD‐1 inhibitors predicts its efficacy . NLR and ANC have been reported to correlate with the number of circulating MDSCs and tumor‐associated neutrophils, which suppress the function of antitumor T cells . Circulating MDSC levels were inversely associated with response rate and survival after treatment with nivolumab in cancer patients .…”

Section: Discussionmentioning

confidence: 99%

“…Several studies have shown that the neutrophil‐to‐lymphocyte ratio (NLR) and the absolute neutrophil count (ANC) in the blood can predict the efficacy of PD‐1 inhibitors in patients with NSCLC . NLR and ANC have also been reported to reflect the number of circulating myeloid‐derived suppressor cells (MDSCs) and tumor‐associated neutrophils, which inhibit the function of antitumor T cells . The immunosuppressive status in the tumor microenvironment could be monitored using the dynamics of NLR and ANC.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Dynamics of blood neutrophil‐related indices during nivolumab treatment may be associated with response to salvage chemotherapy for non‐small cell lung cancer: A hypothesis‐generating study

et al. 2018

View full text Add to dashboard Cite

Several recent studies have shown that salvage chemotherapy following PD‐1 blockade produces high antitumor activity in some patients with non‐small lung cancer (NSCLC). However, the underlying synergistic mechanisms remain uncertain. The blood neutrophil‐to‐lymphocyte ratio (NLR) and absolute neutrophil count (ANC) can reflect the number of circulating myeloid‐derived suppressor cells and tumor‐associated neutrophils. The immunosuppressive status of the tumor microenvironment could be monitored by the time‐series patterns of NLR and ANC. The dynamics of NLR and ANC during nivolumab treatment were retrospectively explored in 15 patients: 8 patients receiving subsequent salvage chemotherapy (2 groups: 3 non‐responders and 5 responders), and 7 responders to nivolumab alone (2 groups: 4 partial response and 3 complete response). The dynamics of NLR and ANC during nivolumab differed among these four groups (NLR P = 0.045, ANC P = 0.067). NLR and ANC during nivolumab treatment increased over time in non‐responders to salvage chemotherapy, with an inverse relationship between drug response and NLR or ANC at four to six weeks among the four groups. We hypothesize that the early dynamics of NLR and ANC during nivolumab may be associated with the late efficacy of subsequent salvage chemotherapy. Further studies involving a large cohort are needed to confirm these findings, which could provide insight into the role of myeloid immunosuppressor cells in combination PD‐1 blockade and chemotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Dynamics of blood neutrophil‐related indices during nivolumab treatment may be associated with response to salvage chemotherapy for non‐small cell lung cancer: A hypothesis‐generating study

et al. 2018

View full text Add to dashboard Cite

show abstract

“…In general, although with some level of heterogeneity, circulating pDCs are decreased in human cancer patients compared to healthy donors, particularly in advanced stage diseases, with a single relevant exception in a study of non-small-cell lung cancer (NSCLC) [144]. Specifically, the peripheral blood pDCs resulted decreased in cohort studies from ovarian cancer [137], NSCLC [145], bladder cancer [146], CRC [147] and advanced breast cancer patients [148]. Notably, in ovarian cancer, circulating pDCs are partially restored after complete remission by chemotherapy [137].…”

Section: Clinical Significance Of the Pdcs Compartment In Human Cancementioning

confidence: 99%

Human Plasmacytoid Dendritic Cells and Cutaneous Melanoma

Monti

Consoli

Vescovi

et al. 2020

Cells

View full text Add to dashboard Cite

The prognosis of metastatic melanoma (MM) patients has remained poor for a long time. However, the recent introduction of effective target therapies (BRAF and MEK inhibitors for BRAFV600-mutated MM) and immunotherapies (anti-CTLA-4 and anti-PD-1) has significantly improved the survival of MM patients. Notably, all these responses are highly dependent on the fitness of the host immune system, including the innate compartment. Among immune cells involved in cancer immunity, properly activated plasmacytoid dendritic cells (pDCs) exert an important role, bridging the innate and adaptive immune responses and directly eliminating cancer cells. A distinctive feature of pDCs is the production of high amount of type I Interferon (I-IFN), through the Toll-like receptor (TLR) 7 and 9 signaling pathway activation. However, published data indicate that melanoma-associated escape mechanisms are in place to hijack pDC functions. We have recently reported that pDC recruitment is recurrent in the early phases of melanoma, but the entire pDC compartment collapses over melanoma progression. Here, we summarize recent advances on pDC biology and function within the context of melanoma immunity.

show abstract

“…CD3+CD4+ absolute number also affects the treatment effect and prognosis of disease. Predicting long-term DFS of cancer patients immediately after surgical resection of clinically localized and advanced disease is of great value for patient counseling, identifying poor risk-group who might bene t from enrollment in adjuvant therapy protocols [33]. Prognosis of cancer patients is based not only on tumor-related factors, but also on host-related factors, including systemic immune cell activation [34].…”

Section: Al Affecting Disease-free Survivalmentioning

confidence: 99%

The clinical value of the changes of peripheral lymphocyte subsets absolute counts in patients with non-small cell lung cancer

Xia

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Immune function strongly influences the outcome of patients with non-small cell lung cancer(NSCLC). It’s vital to understand the immune state of patients through detecting the level of lymphocyte subsets including percentage and number timely and accurately, and helpful to evaluate conditions of prognosis and adjust the treatment program for patients.Methods: Blood sample was obtained from 172 patients with NSCLC and 55 normal controls(NCs).The absolute count and percentages of CD3+,CD3+CD4+,CD3+CD8+, B and NK cells were determined by flow cytometry simultaneously with single platform technologies. Then 172 patients were followed up for the study of effects of the lymphocyte on disease progression and disease free survival(DFS). The factors affecting disease progression were analyzed by Binary Logistic regression.Calculating survivals were with the method of Kaplan-Meier. The log-rank test and proportional hazard regression model (enter method) were used for univariable and multivariable analyses respectively. Results: The absolute counts of CD3+, CD3+CD4+, CD3+CD8+, B and NK cells were significantly decreased in patients contrasted with NCs(P<0.05), no difference in percentages(P>0.05) except NK cells between patients and NCs. Relative to NCs, patients with NSCLC at stage Ⅰ and Ⅱ had lower absolute count of lymphocyte subsets(P<0.01), patients at stage Ⅲ~Ⅳ were also significantly lower compared with those in control group (P<0.01), no significant differences were observed in the percentages between patients and NCs. Compared the absolute counts of CD3+, CD3+CD4+, CD3+CD8+, B and NK cells among patients at different stages, only CD3+CD4+ was associated with clinical stages obviously. Patients with treatment of chemotherapy after surgery or only surgery showed different effects on absolute counts of CD3+CD4+,CD3+CD8+, NK and B cells . Binary Logistic regression showed CD3+CD4+ and CD3+CD8+ could contribute to favorable prognosis. Multivariate analysis of prognostic factors of DFS showed CD3+CD4+ cell was independent factor for predicting DFS .Conclusions:Compared to NCs, patients with NSCLC at different stages showed decreased absolute lymphocyte count obviously, rather than lymphocyte percentage, which persists for months or years after chemotherapy. The high level of baseline absolute CD3+CD4+ cells count(>502 cells/ul) contributed to longer disease free survival.Chinese Clinic Trial Registry number:ChiCTR-IOR-17014139; Registry date:2017/12/25

show abstract

Blood immune cell biomarkers in lung cancer

Cited by 54 publications

References 50 publications

Dynamics of blood neutrophil‐related indices during nivolumab treatment may be associated with response to salvage chemotherapy for non‐small cell lung cancer: A hypothesis‐generating study

Dynamics of blood neutrophil‐related indices during nivolumab treatment may be associated with response to salvage chemotherapy for non‐small cell lung cancer: A hypothesis‐generating study

Human Plasmacytoid Dendritic Cells and Cutaneous Melanoma

The clinical value of the changes of peripheral lymphocyte subsets absolute counts in patients with non-small cell lung cancer

Contact Info

Product

Resources

About